Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar Trends Report

- PMLiVE

New outcomes data could unlock Repatha’s potential, says Amgen

Evidence of significant cardiovascular benefit could boost slow sales for projected blockbuster

Roche Basel Switzerland

Tecentriq growth offsets Avastin’s US decline at Roche

Shifts focus to newer therapies in anticipation of brewing biosimilar competition

- PMLiVE

AbbVie weak on new drug sales, but Humira stays strong

World’s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe

Research Partnership

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

Novartis Gehry Building

Novartis ‘reviewing options’ for Alcon division

Possible sale or spin-off in store for eyecare unit as firm reports Q4 operating loss of $132m

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

Choose or lose

The divergence of business models demands brave choices

Sanofi reception

Lilly and Boehringer launch first Lantus clone Basaglar in US

Starts biosimilar at 15% discount to Sanofi’s basal insulin product

Actelion HQ Switzerland

Resurgent Actelion catches J&J’s eye

Confirms talks of possible take over after Uptravi sees ‘outstanding’ sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links